Methods for glucagon suppression using modified exendins

• US 20070037750A1
• Filed: 10/19/2006
• Published: 02/15/2007
• Est. Priority Date: 01/14/1999
• Status: Active Grant

• Current Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Young, Andrew, Gedulin, Bronislava
• Granted Patent: US 7,407,932 B2
• Time in Patent Office: Days
• US Class Current: 514/11.700
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 5/48 of the pancreatic hormones
• CPC Class Codes: C07K 14/57563 Vasoactive intestinal peptide [VIP]; Related peptides

Abstract

Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provided. These methods are are useful in treating hyperglucagonemia and other conditions that would be benefited by lowering plasma glucgon or suppressing glucagon secretion.

Claims

1. A method of lowering plasma glucagon in a subject, comprising administering to said subject a therapeutically effective glucagon lowering amount of a compound selected from the group consisting of an exendin, an an exendin agonist, a modified exendin and a modified exendin agonist.

2. The method of claim 1 wherein said subject is suffering from necrolytic migratory erythema.

3. The method of claim 1 wherein said subject has a glucagonoma.

4. The method of any of claims 1-3 wherein said exendin agonist is an exendin.

5. The method of claim 4 wherein said exendin is exendin-4.

6. The method of any of claims 1-3 or 4 wherein said subject is a human.

7. The method of any of claims 1-3 wherein said modified exendin or exendin agonist is linked to one or more polyethylene glycol polymers.

8. The method of claim 7, wherein said one or more polyethylene glycol polymers each have molecular weights between 500 and 20,000.